In preclinical models of KRAS-mutant lung cancer, the use of IL-1β inhibitors has been shown to reduce tumor burden, increase the infiltration of CD8+ T cells into the TME, elevate IFN-γ levels, decrease PD-1 expression, and reduce the number of exhausted PD-1+ T cells [96]. This evidence concerns the gene IL1B and lung cancer.